Toborinone

Toborinone is an inotropic agent. Toborinone increases cAMP and intracellular calcium levels through inhibiting PDE. Toborinone inhibits thrombin-induced platelet aggregation with an IC50 of 9.7 μM[1][2].

Product Specifications

CAS Number

[143343-83-3]

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

COC1=C(C=CC(CNCC(COC2=CC=C3C(C=CC(N3)=O)=C2)O)=C1)OC

Molecular Formula

C21H24N2O5

Molecular Weight

384.43

References & Citations

[1]MacGowan G. A. (2000) . Clinical overview of the novel inotropic agent toborinone. Expert opinion on investigational drugs, 9 (5), 1109-1117.|[2]Kageyama, K., et al., (2004) . Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry. Journal of anesthesia, 18 (2), 107-112.